Shopping Cart
- Remove All
Your shopping cart is currently empty
PNU-159682, a metabolite of anthracycline nemorubicin, is a DNA topoisomerase II inhibitor with excellent cytotoxicity.

| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $84 | In Stock | |
| 5 mg | $198 | In Stock | |
| 10 mg | $363 | In Stock | |
| 25 mg | $596 | In Stock | |
| 50 mg | $816 | In Stock | |
| 100 mg | $1,070 | In Stock | |
| 1 mL x 10 mM (in DMSO) | $292 | In Stock |
| Description | PNU-159682, a metabolite of anthracycline nemorubicin, is a DNA topoisomerase II inhibitor with excellent cytotoxicity. |
| Targets&IC50 | Topo II unknotting activity:100 μM, CA IX:25 nM |
| In vitro | PNU-159682 inhibits a panel of human tumor cell lines (IC70 values in the range of 0.07-0.58 nM). PNU-159682 is 2,360- to 790-fold and 6,420- to 2,100-fold more potent than MMDX and doxorubicin, respectively. PNU-159682 displays cytotoxic effect on CAIX-expressing SKRC-52 cells (IC50: 25 nM). PNU-159682 (10 μM)-DNA adducts contain one or two drug molecules bound to double-stranded DNA. PNU-159682 (100 μM) weakly inhibits topoisomerase II unknotting activity [1][2][3]. |
| In vivo | PNU-159682 (25 nmol/kg) shows an effective antitumor effect in mice bearing SKRC-52 xenografted tumors. PNU-159682 (15 μg/kg, i.v.) displays antitumor activity in mice bearing disseminated murine L1210 leukemia and in MX-1 human mammary carcinoma xenografts at 4 μg/kg[1][3]. |
| Molecular Weight | 641.62 |
| Formula | C32H35NO13 |
| Cas No. | 202350-68-3 |
| Smiles | CO[C@H]1OCCN2[C@H]3C[C@H](O[C@H]4C[C@@](O)(Cc5c(O)c6C(=O)c7cccc(OC)c7C(=O)c6c(O)c45)C(=O)CO)O[C@@H](C)[C@H]3O[C@H]12 |
| Relative Density. | 1.58 g/cm3 (Predicted) |
| Color | Red |
| Appearance | Liquid |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 96.7 mg/mL (150.71 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 3.3 mg/mL (5.14 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.